Holen Sie sich die Stockscreener-App
42.03
1.69%
0.70
Vorhandelsmarkt:
42.03
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$41.33
Offen:
$41.82
24-Stunden-Volumen:
1.78M
Relative Volume:
0.70
Marktkapitalisierung:
$5.81B
Einnahmen:
$264.79M
Nettoeinkommen (Verlust:
$-14.36M
KGV:
-382.09
EPS:
-0.11
Netto-Cashflow:
$-28.11M
1W Leistung:
+13.69%
1M Leistung:
+5.44%
6M Leistung:
+72.61%
1J Leistung:
+212.03%
1-Tages-Spanne:
$40.95
$42.46
1-Wochen-Bereich:
$37.48
$42.46
52-Wochen-Spanne:
$12.93
$43.32
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Vergleichen Sie TGTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
42.03 | 5.81B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
TG Therapeutics (NasdaqCM:TGTX) Sees Profitable Turn With Strong Quarterly Earnings - Yahoo Finance
TG Therapeutics: Considering If The Promise Of Accelerated Revenue Growth Is Enough - Seeking Alpha
2 Reasons to Sell ESTC and 1 Stock to Buy Instead - The Globe and Mail
Where are the Opportunities in (TGTX) - news.stocktradersdaily.com
Exploring US High Growth Tech Stocks - simplywall.st
TG Therapeutics: Progress In MS Tempered By High Expectations (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by LPL Financial LLC - MarketBeat
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting | TGTX Stock News - GuruFocus
TG Therapeutics shares data on multiple sclerosis treatment By Investing.com - Investing.com South Africa
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why - MSN
TG Therapeutics Shares Rise Almost 30% In 3 Months: Here's Why - Barchart.com
TGTX: Promising Short Squeeze Opportunity with Biopharma Focus - GuruFocus
TG Therapeutics (TGTX) Highlights New Research on BRIUMVI® for M - GuruFocus
TG Therapeutics (TGTX) Struggles with Low ROE Despite High Debt - GuruFocus
TG Therapeutics Announces Data Presentations for BRIUMVI in Mult - GuruFocus
TG Therapeutics shares data on multiple sclerosis treatment - Investing.com
TG Therapeutics Announces Data Presentations for BRIUMVI in - GlobeNewswire
Game-Changing MS Treatment? BRIUMVI Single-Dose Trial Reveals Breakthrough Potential - Stock Titan
TG Therapeutics (TGTX) Shares Jump Amid Strong Briumvi Sales - GuruFocus
TG Therapeutics (TGTX) Highlights BRIUMVI® Data at Neurology Mee - GuruFocus
Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet? - simplywall.st
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - The Manila Times
TG Therapeutics showcases BRIUMVI data at neurology meet - Investing.com
Game-Changing MS Treatment: BRIUMVI Reveals Exceptional Real-World Safety Profile - Stock Titan
Buy Rating for TG Therapeutics Driven by Promising Briumvi Data and Strong Revenue Projections - TipRanks
TG Therapeutics reports on MS treatment switch By Investing.com - Investing.com South Africa
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals - GlobeNewswire
TG Therapeutics reports on MS treatment switch - Investing.com
Medical Journals Reveal Breakthrough: BRIUMVI Succeeds Where Other MS Treatments Fall Short - Stock Titan
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and TG Therapeutics (TGTX) - The Globe and Mail
(TGTX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
TGTX Gains as Roche's Ocrevus Fails in Phase 3 Trial; Impacting MS Market Dynamics - GuruFocus
TG Therapeutics rises after trial setback for high dose version of Roche’s MS drug - MSN
TG Therapeutics stock rises as Roche’s trial fails (TGTX) - Seeking Alpha
CRUCIAL INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm - ACCESS Newswire
Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%? - Yahoo Finance
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - MSN
Why TG Therapeutics Stock Was Soaring This Week - MSN
Based On Its ROE, Is TG Therapeutics, Inc. (NASDAQ:TGTX) A High Quality Stock? - simplywall.st
(TGTX) Investment Analysis and Advice - Stock Traders Daily
TG Therapeutics stock soars to 52-week high of $43.03 By Investing.com - Investing.com India
TG Therapeutics stock soars to 52-week high of $43.03 - Investing.com
TG Therapeutics (TGTX) technical analysisTG Therapeutics (NASDAQ:TGTX) - Benzinga
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):